Drug intelligence / Profile preview

metformin + dapagliflozin

Development stage: Unknown
Lead developer: Dongwha Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DW6013 is a fixed-dose combination (FDC) sustained-release (SR) small molecule therapy being developed by Dong Wha Pharm for the treatment of type 2 diabetes mellitus. It consists of metformin, a biguanide that suppresses hepatic glucose production and enhances peripheral insulin sensitivity, and dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that promotes urinary glucose excretion by blocking renal reabsorption. The sustained-release formulation is designed to maintain therapeutic plasma concentrations over an extended period, potentially improving gastrointestinal tolerability and patient adherence compared to immediate-release versions. DW6013 is currently undergoing Phase 1 clinical evaluation to assess its pharmacokinetic profile and bioequivalence compared to the individual components.

Other names: Dapagliflozin + Metformin SRMetformin hydrochloride + Dapagliflozin propanediol

Targets

ND1 (Mitochondrial electron transport chain complex I)SGLT2 (Sodium-glucose cotransporter protein subunit 2)AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on metformin + dapagliflozin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metformin + dapagliflozin.

Explore the full profile